Conexeu Sciences Initiates Preclinical 3D-Bioprinted Breast Matrix Program with Wake Forest Institute for Regenerative Medicine
核心洞察
Conexeu Sciences has launched a preclinical development program for its B.R.E.A.S.T.™ 3D-bioprinted matrix at the Wake Forest Institute for Regenerative Medicine (搜索), one of the world's largest regenerative medicine research centers.
The program will evaluate durability, host tissue integration, and resorbability of the CXU™ (搜索) platform's 3D-printed matrix using WFIRM's advanced Integrated Tissue-Organ Printing System (iTOPS).
Conexeu's CXU™ (搜索) is an extracellular matrix–based platform targeting multiple markets including wound care, aesthetics, and breast reconstruction, with a 510(k) submission anticipated in early 2027.
Conexeu Sciences Inc. (搜索) (NASDAQ: CNXU), an early-stage regenerative medicine company that began trading on the Nasdaq on May 21, 2026, has initiated a preclinical development program for its B.R.E.A.S.T.™ (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE™) 3D-bioprinted matrix at the Wake Forest Institute for Regenerative Medicine (搜索) (WFIRM), part of Wake Forest University School of Medicine and Advocate Health. The announcement, made on May 27, 2026, marks a significant step for the company's proprietary CXU™ (搜索) extracellular matrix–based platform and its ambition to move breast reconstruction beyond traditional silicone implants.
The collaboration leverages WFIRM's Integrated Tissue-Organ Printing System (iTOPS), one of the most advanced bioprinting platforms in operation globally. WFIRM houses over 500 researchers working across more than 40 different tissues and organs, and its track record includes the first engineered organ implanted in a patient and 18 distinct cell and tissue therapy technologies used in human patients.
"This preclinical program design is an important step in the advancement of B.R.E.A.S.T.™ and our overall regenerative medicine strategy," said Miles Harrison, President and CEO of Conexeu. "Access to world-class tools at WFIRM, a globally recognized leader in bioprinting research, gives us both the scientific rigor and the infrastructure to develop our 3D-printed matrix responsibly, and to build the evidence base that future clinical investigation will require."
Preclinical Program Design and Objectives
The research program will evaluate three critical properties of Conexeu's CXU™ (搜索) 3D-printed B.R.E.A.S.T.™ matrix: durability under physiological conditions, host tissue integration, and resorbability over time. These findings will directly inform the design of future studies and guide the path toward clinical investigation.
The bridge between Conexeu and WFIRM is the RegenMed Development Organization (ReMDO), a 501(c)(3) non-profit established to de-risk regenerative medicine technologies and accelerate translation to clinical practice. Joshua Hunsberger, PhD, Chief Technology Officer of ReMDO, stated: "The tissue-organ printing system at WFIRM is one of the tools that allows ReMDO to deliver on its mission — accelerating the translation of regenerative medicine technologies by de-risking innovative products and advancing scalable biomanufacturing. Conexeu Sciences' progress on 3D printing is a strong example of that work in action."
The CXU™ (搜索) Platform Strategy
B.R.E.A.S.T.™ represents the most visible application of Conexeu's technology, but the company's strategic thesis rests on the CXU™ (搜索) platform itself — an extracellular matrix–based system built on what management describes as a single structural principle: one formula, one device, designed to scale across multiple addressable markets without reformulation.
The lead device candidate, Ten Minute Tissue™, is an ECM-based device engineered to remain fluid at room temperature and transition to a stable gel at body temperature in approximately ten minutes. Preclinical work has demonstrated organized scaffold formation, a favorable inflammatory profile, and support for cell migration, proliferation, and new tissue formation.
Conexeu is targeting large, multi-billion-dollar end markets including wound care, dental applications, and facial and body contouring — encompassing GLP-1–driven loose skin — with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The company's intellectual property position includes issued patents covering the United States, European Union, Japan, and Australia, with additional filings pending. Conexeu holds all rights, title, and interest in the platform IP, with no royalty or licensing obligations.
Management is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.
The Clinical Need in Breast Reconstruction
The clinical rationale for the B.R.E.A.S.T.™ program is grounded in significant unmet need. For more than fifty years, breast reconstruction has predominantly relied on silicone implants — devices designed to restore shape and volume but not to regenerate the breast's own living tissue. According to the company, roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy each year choose not to pursue reconstruction at all, a statistic that underscores the limitations of current options.
Competitive Landscape and Market Context
The regenerative medicine sector is experiencing rapid expansion. Independent market estimates place the broad regenerative medicine market in the tens of billions of dollars in 2026, with projections from Business Research Insights indicating growth from approximately $47.4 billion in 2025 to roughly $230.4 billion by 2034, representing a compound annual growth rate of 19.2%.
Several publicly traded companies operating in adjacent territory have reported recent financial results that illustrate the sector's momentum. Establishment Labs Holdings Inc. (NASDAQ: ESTA), maker of the Motiva® line of silicone gel-filled breast implants, reported first quarter 2026 revenue of $59.9 million, up 44.7% year-over-year, and has surpassed more than five million Motiva devices in market across more than 100 countries. TELA Bio, Inc. (NASDAQ: TELA), which focuses on soft-tissue reconstruction solutions emphasizing preservation and restoration of the patient's own anatomy, reported first quarter 2026 revenue of $19.1 million with international sales surging 41% year-over-year. Its OviTex® portfolio has reached approximately 90,000 implantations globally.
InMode Ltd. (搜索) (NASDAQ: INMD), positioned in the body contouring and skin tightening segment including the GLP-1–driven skin laxity category, reported first quarter 2026 GAAP revenue of $82.0 million. Pacira BioSciences, Inc. (搜索) (NASDAQ: PCRX) reported first quarter 2026 revenue of $177 million and is advancing PCRX-201, a gene therapy vector platform that received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
Risks and Forward Outlook
Conexeu remains a preclinical, pre-revenue company, and the path to commercialization carries substantial execution risk. As disclosed in the company's regulatory filings, preclinical results generated through the WFIRM program may not be predictive of results in future clinical studies or in human patients. There is no assurance that the anticipated 510(k) submission in early 2027 will result in clearance or approval on the anticipated timeline, on favorable terms, or at all. The markets Conexeu targets are served by established, well-capitalized competitors with significantly greater resources, clinical data, regulatory approvals, and market presence.
The company currently has 25,269,996 shares issued and outstanding and 35,238,222 shares on a fully diluted basis. Chairman Jeff Sharpe characterized the Nasdaq listing as "an important milestone in Conexeu's evolution as we enter the public markets during an important period of advancement across regenerative medicine, biomaterials science, and tissue restoration."
For investors and clinicians tracking the evolution of regenerative medicine, the WFIRM program represents the next data point that will determine whether Conexeu's platform thesis translates from preclinical promise into clinical viability.